The Effect of Omega Galil Hazelnut Chocolate Spread "O'Sweet Spread" With 80% Reduced Sucrose on Glucose Response of People With TID

Launched by RABIN MEDICAL CENTER · Mar 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new chocolate spread called "O'Sweet," which has 80% less sugar than regular spreads. It aims to see how this reduced-sugar spread affects blood sugar levels in people with Type 1 Diabetes (T1D) compared to a popular spread called Nutella. The researchers want to find out if O'Sweet can help maintain better blood sugar control after meals, which is important for people managing diabetes. They will also ask participants how they feel about the taste of O'Sweet compared to Nutella.

To be eligible for this study, participants should be between 18 and 35 years old, have had diabetes for more than a year, and have a healthy weight. They should also use a Continuous Glucose Monitoring system to track their blood sugar levels. During the trial, participants will be randomly assigned to try both spreads on different days. This means everyone will have a chance to taste both O'Sweet and Nutella while helping researchers learn more about managing blood sugar levels in diabetes. If you’re interested, keep in mind that certain health conditions or medications may prevent you from joining the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • T1D patients with diabetes duration \>1 year
• • 18-35 years of age
• • Normal weight (BMI 20- 30 kg/m2)
• • Non-smoker
• • Hemoglobin A1C \<9%
• • Patient treated with Continuous Glucose Monitoring system (CGM's)
• Exclusion Criteria:
• • Acute Upper Respiratory Tract Infection (URTI) within 2 weeks of enrollment
• • A gastro-intestinal condition that could disrupt intestinal absorption or motility, and thereby impair postprandial glucose absorption (e.g. diabetic gastroparesis, celiac disease, or malabsorption).
• • A chronic illness in the past 5 years, including among others inflammatory, metabolic, neoplastic, and congenital disease.
• • Use of medications other than insulin (e.g. Antibiotics/antifungal, analgesics) during the study and 2 weeks before enrollment;
• • Neuro-psychiatric disorders
• • Known food allergies or intolerances
• • Self-reported sinus, taste or smell dysfunction
• • Pregnant or lactating women